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Abstract. In this study, we performed exome-wide association 
studies (EWASs) to identify genetic variants that confer suscep-
tibility to ischemic stroke, intracerebral hemorrhage (ICH), 
or subarachnoid hemorrhage (SAH). EWAS for ischemic 
stroke was performed using 1,575 patients with this condi-
tion and 9,210 controls, and EWASs for ICH and SAH were 
performed using 673 patients with ICH, 265 patients with SAH 
and 9,158 controls. Analyses were performed with Illumina 
HumanExome-12 DNA Analysis BeadChip or Infinium 
Exome-24 BeadChip arrays. The relation of allele frequencies 
for 41,339 or 41,332 single nucleotide polymorphisms (SNPs) 
that passed quality control to ischemic or hemorrhagic stroke, 
respectively, was examined with Fisher's exact test. Based 
on Bonferroni's correction, a P-value of <1.21x10-6 was 
considered statistically significant. EWAS for ischemic stroke 
revealed that 77 SNPs were significantly associated with this 
condition. Multivariable logistic regression analysis with 
adjustment for age, sex and the prevalence of hypertension 
and diabetes mellitus revealed that 4 of these SNPs [rs3212335 
of GABRB3 (P=0.0036; odds ratio, 1.29), rs147783135 of 
TMPRSS7 (P=0.0024; odds ratio, 0.37), rs2292661 of PDIA5 
(P=0.0054; odds ratio, 0.35) and rs191885206 of CYP4F12 
(P=0.0082; odds ratio, 2.60)] were related (P<0.01) to ischemic 
stroke. EWASs for ICH or SAH revealed that 48 and 12 SNPs, 
respectively, were significantly associated with these condi-
tions. Multivariable logistic regression analysis with adjustment 
for age, sex and the prevalence of hypertension revealed that 
rs138533962 of STYK1 (P<1.0x10-23; odds ratio, 111.3) was 
significantly (P<2.60x10-4) associated with ICH and that 
rs117564807 of COL17A1 (P=0.0009; odds ratio, 2.23x10-8) 
was significantly (P<0.0010) associated with SAH. GABRB3, 
TMPRSS7, PDIA5 and CYP4F12 may thus be novel suscepti-
bility loci for ischemic stroke, whereas STYK1 and COL17A1 
may be such loci for ICH and SAH, respectively.
Introduction
Stroke is a common and serious condition, with approximately 
795,000 individuals having experienced a new or recurrent 
stroke and 128,978 stroke-related deaths having occurred in the 
United States in 2013. The prevalence of stroke in the United 
States was approximately 6.6 million in 2012, with 87% of 
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these events being ischemic stroke, 10% intracerebral hemor-
rhage (ICH) and 3% subarachnoid hemorrhage (SAH) (1). 
Despite recent advances in acute therapy, stroke remains the 
leading cause of severe disability and the fifth leading cause 
of mortality (after heart disease, cancer, chronic lower respi-
ratory disease and accidents) in the United States (1). Given 
that stroke is a life-threatening condition, its prevention is an 
important goal for reducing its overall burden. The identifica-
tion of biomarkers for stroke risk is key both for risk prediction 
and for potential intervention to avert future cerebrovascular 
events.
Ischemic stroke is a complex multifactorial disorder that 
is thought to result from an interaction between a person's 
genetic background and various environmental factors (2). 
The heritability of ischemic stroke has been estimated to be 
40.3% for large-vessel disease, 32.6% for cardioembolic stroke, 
16.1% for small-vessel disease and 37.9% for ischemic stroke 
as a whole (3). Genome-wide association studies (GWASs) in 
European ancestry populations have identified various genes 
and loci that confer susceptibility to ischemic stroke (4-11), 
with one recent large-scale study having identified HDAC9 
and chromosome 1p13.2 (near TSPAN2) as susceptibility loci 
for large-vessel disease, PITX2 and ZFHX3 as such loci for 
cardioembolic stroke, and 12q24 (near ALDH2) as a suscep-
tibility locus for small-vessel disease, indicating that ischemic 
stroke-related loci are subtype specific (12).
ICH accounts for a large proportion of severe or fatal 
cases of stroke, with its most important risk factors being 
advanced age and hypertension (13). ICH is usually attributed 
to hypertensive small-vessel disease, with the most common 
sites of hemorrhage including the basal ganglia, cerebellum 
and pons (13,14). In some cases, however, the hemorrhage is 
lobar in location, such as in the frontal, parietal, temporal or 
occipital cortex, and such patients often do not have hyperten-
sion (14). The occurrence of lobar ICH has been shown to be 
associated with the ε2 and ε4 alleles of the apolipoprotein E 
gene (APOE) (15,16). This relation of lobar ICH to APOE is 
presumably due to the association of this gene with cerebral 
amyloid angiopathy (17). The heritability of deep or lobar ICH 
has been estimated to be 34 and 73%, respectively (18), although 
genetic factors may influence, not only the development of 
ICH, but also hypertension (19). A previous meta-analysis of 
GWASs for ICH in European ancestry populations identified 
chromosome 12q21.1 (near TRHDE) as a susceptibility locus 
for lobar ICH and 1q22 (near PMF1-SCL25A44) as such a 
locus for nonlobar ICH (20).
SAH is commonly caused by the rupture of an aneu-
rysm in an intracranial artery (21,22). Although the 
incidence of aneurysmal SAH in the general population is low 
(~8/100,000 person-years) (23), a young age at onset and poor 
prognosis result in the loss of productive life-years similar to that 
for ischemic stroke (24). Given that a family history is an impor-
tant risk factor for the development of intracranial aneurysm, 
genetics may play an important role in the development of this 
condition (25). GWASs have implicated several loci and genes 
as conferring susceptibility to intracranial aneurysm (26-31), 
with a meta-analysis of such studies having identified 19 genetic 
variants related to this condition (32).
Most genetic variants identified by GWASs for ischemic 
stroke, ICH, or intracranial aneurysm have a minor allele 
frequency (MAF) of >5% and a small individual effect size. 
Given that these common variants explain only a fraction 
of the heritability of ischemic and hemorrhagic stroke, it is 
expected that low-frequency (MAF of 0.5-5%) or rare (MAF 
of <0.5%) variants with larger effect sizes contribute to the 
genetic architecture of these conditions (33). Although several 
polymorphisms have been found to be significantly associated 
with ischemic stroke (34-36) or intracranial aneurysm (30) in 
Japanese individuals, genetic variants, including low-frequency 
and rare variants, that contribute to genetic susceptibility to 
ischemic stroke, ICH or SAH in Japanese individuals remain 
to be identified definitively.
In this study, we performed exome-wide association 
studies (EWASs) with the use of exome array-based genotyping 
methods to identify single nucleotide polymorphisms (SNPs) 
and in particular, low-frequency or rare coding variants with 
moderate to high effect sizes, that confer susceptibility to 
ischemic stroke, ICH, or SAH in Japanese individuals. Given 
that most of the known low-frequency or rare variants were not 
included in the arrays adopted in previous GWASs for these 
conditions, we applied Illumina arrays that provide coverage 
of functional SNPs in entire exons, including such variants.
Materials and methods
Study subjects. For EWAS of ischemic stroke, 1,575 patients 
with ischemic stroke and 9,210 control individuals were exam-
ined, whereas for EWASs of hemorrhagic stroke, 673 patients 
with ICH, 265 patients with SAH and 9,158 controls were 
examined. The majority of the control individuals were the 
same for the studies of ischemic and hemorrhagic stroke. 
The subjects were recruited from individuals who either 
visited outpatient clinics of or were admitted to participating 
hospitals (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu 
Prefectural General Medical Center, Gifu; Japanese Red 
Cross Nagoya First Hospital, Nagoya; Inabe General Hospital, 
Inabe; Hirosaki University Hospital and Hirosaki Stroke 
and Rehabilitation Center, Hirosaki, Japan) due to various 
symptoms or for an annual health checkup between 2002 
and 2014; were community-dwelling individuals recruited 
to a population-based cohort study in Inabe between 2010 
and 2014 or in Tokyo or Kusatsu between 2011 and 2015; or 
were cases of autopsy performed at the Tokyo Metropolitan 
Geriatric Hospital from 1995 to 2012.
The diagnosis of ischemic stroke, ICH, or SAH was based 
on the occurrence of a new and abrupt focal neurological deficit, 
with neurological symptoms and signs persisting for >24 h, and 
it was confirmed by positive findings in computed tomography 
or magnetic resonance imaging (or both) of the head. The 
type of stroke was determined according to the Classification 
of Cerebrovascular Diseases III (37). Given that suscepti-
bility loci for ischemic stroke are subtype-specific (12), we 
examined subjects with atherothrombotic cerebral infarc-
tion (large-vessel disease).
For the study of ischemic stroke, subjects with cardiogenic 
embolic stroke, lacunar infarction alone, transient ischemic 
attack, hemorrhagic stroke, cerebrovascular malformations, 
moyamoya disease, cerebral venous sinus thrombosis, brain 
tumors, or traumatic cerebrovascular diseases were excluded 
from enrollment. For the studies of hemorrhagic stroke, 
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individuals with ischemic stroke, lacunar infarction, transient 
ischemic attack, intracranial hemorrhage resulting from 
cerebrovascular malformations, moyamoya disease, cerebral 
venous sinus thrombosis, brain tumors, traumatic cerebro-
vascular diseases, or subdural hematoma were excluded. The 
control individuals had no history of ischemic or hemorrhagic 
stroke; of aortic, coronary, or peripheral artery disease; 
or of other thrombotic, embolic or hemorrhagic disorders. 
Individuals with unruptured intracranial aneurysm were also 
excluded from the controls. The absence of stroke history was 
evaluated with a detailed questionnaire and was confirmed by 
the absence of a history of neurological deficits. Autopsy cases 
were excluded from the controls.
Body mass index was calculated as follows: body mass 
index = body weight (kg)/[body height (m)]2. Blood pres-
sure was measured at least twice with subjects having first 
rested in the sitting position for >5 min; the measurements 
were taken by a skilled physician or nurse. Venous blood 
was collected in the early morning after the subjects had 
fasted overnight. Plasma glucose level, blood hemoglobin 
A1c, and serum concentrations of triglycerides, high density 
lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-
cholesterol, and creatinine were measured with automated 
analyzers at the clinical laboratory of each hospital. Estimated 
glomerular filtration rate (eGFR) was calculated as follows: 
eGFR (ml/min/1.73 m2) = 194 x [age (years)]-0.287 x [serum 
creatinine (mg/dl)]-1.094 x [0.739 if female]. Chronic kidney 
disease was defined as an eGFR of <60 ml/min/1.73 m2.
The study protocol complied with the Declaration of 
Helsinki and was approved by the Committees on the Ethics 
of Human Research of Mie University Graduate School of 
Medicine, Tokyo Metropolitan Institute of Gerontology, 
Hirosaki University Graduate School of Medicine, and partici-
pating hospitals. Written informed consent was obtained from 
each participant or the families of the deceased subjects.
EWASs. Venous blood (5 or 7 ml) was collected into tubes 
containing 50 mmol/l ethylenediaminetetraacetic acid (diso-
dium salt), peripheral blood leukocytes were isolated and 
genomic DNA was extracted from these cells either with a DNA 
extraction kit (Genomix; Talent, Trieste, Italy; or SMITEST 
EX-R&D; Medical and Biological Laboratories, Nagoya, 
Japan) or by standard protocols based on phenol-chloroform 
extraction and spin columns. In autopsy cases, genomic DNA 
was extracted from the kidneys. EWASs were performed with 
the use of a HumanExome-12 v1.1 or v1.2 DNA Analysis 
BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, 
San Diego, CA, USA), both of which include putative func-
tional exonic variants selected from >12,000 individual 
exome and whole-genome sequences. The exonic content of 
~244,000 SNPs represents diverse populations, including 
European, African, Chinese and Hispanic individuals (38). 
SNPs contained in only one of the exome arrays (~3.6% of 
all SNPs) were excluded from the analysis. We performed 
quality control (39) as follows: i) genotyping data with a call 
rate of <97% were discarded, with the mean call rate for the 
remaining data being 99.9%; ii) sex specification was examined 
for all samples, and those for which sex phenotype in the clin-
ical records was inconsistent with genetic sex were discarded; 
iii) duplicated samples and cryptic relatedness were examined 
by calculation of identity by descent; all pairs of DNA samples 
showing identity by descent of >0.1875 were inspected, and 
one sample from each pair was excluded; iv) heterozygosity 
of SNPs was calculated for all samples, with those showing 
extremely low or high heterozygosity (>3 standard deviations 
from the mean) being discarded; v) SNPs in sex chromosomes 
or in mitochondrial DNA were excluded from the analysis, as 
were non-polymorphic SNPs or SNPs with a MAF of <0.001; 
vi) SNPs whose genotype distributions deviated signifi-
cantly (P<0.001) from Hardy-Weinberg equilibrium in control 
individuals were discarded; vii) genotype data were exam-
ined for population stratification by principal components 
analysis (40), and population outliers were excluded from the 
analysis. A total of 41,339 and 41,332 SNPs that passed quality 
control for the studies of ischemic and hemorrhagic stroke, 
respectively, were subjected to analysis.
Statistical analysis. For the analysis of characteristics of the 
study subjects, quantitative data were compared between 
subjects with ischemic stroke, ICH or SAH and controls 
with the Mann-Whitney U test, given that variables exhibited 
skewed distribution (P<0.01 by the Kolmogorov-Smirnov 
and Lilliefors test). Categorical data were compared between 
two groups with Fisher's exact test. Allele frequencies were 
estimated by the gene counting method, and Fisher's exact 
test was applied to identify departure from Hardy-Weinberg 
equilibrium. Allele frequencies of SNPs were compared 
between subjects with ischemic stroke, ICH or SAH and the 
controls with Fisher's exact test. Given that the Fisher's exact 
test gives exact P-values, it is appropriate to use this test to 
examine the relation of low frequency or rare variants to 
phenotypes. To compensate for multiple comparisons of 
genotypes with ischemic stroke, ICH or SAH, we applied 
Bonferroni's correction for statistical significance of asso-
ciation. Given that 41,339 or 41,332 SNPs were analyzed for 
ischemic and hemorrhagic stroke, respectively, the signifi-
cance level was set at P<1.21x10-6 (0.05/41,339 or 0.05/41,332) 
for each EWAS. Quantile-quantile plots for P-values of allele 
frequencies in EWASs for ischemic stroke, ICH and SAH are 
shown in Fig. 1. The inflation factor (λ) was 1.30 for ischemic 
stroke, 1.52 for ICH, and 1.72 for SAH. Multivariable logistic 
regression analysis was performed with ischemic stroke as a 
dependent variable and independent variables including age, 
sex (0, woman; 1, man), the prevalence of hypertension and 
diabetes mellitus (0, no history of these conditions; 1, posi-
tive history) and genotype of each SNP. Similar analysis was 
performed with ICH or SAH as a dependent variable and 
independent variables including age, sex, the prevalence of 
hypertension and genotype of each SNP. Genotypes of each 
SNP were assessed according to dominant [0, AA; 1, AB + 
BB (A, major allele; B, minor allele)], recessive (0, AA + AB; 
1, BB) and additive genetic models, and the P-value, odds ratio 
and 95% confidence interval were calculated. Additive models 
comprised additive 1 (0, AA; 1, AB; 0, BB) and additive 2 (0, 
AA; 0, AB; 1, BB) scenarios, which were analyzed simultane-
ously with a single statistical model. The relation of genotypes 
of SNPs to intermediate phenotypes was examined with 
Fisher's exact test (2x2) or Pearson's Chi-square test (2x3). 
Bonferroni's correction was also applied to other statistical 
analysis as indicated. Statistical tests were performed with 
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JMP Genomics version 6.0 software (SAS Institute, Cary, NC, 
USA).
Results
EWAS for ischemic stroke. The characteristics of the subjects 
enrolled in the study are shown in Table I. Age, the frequency of 
the male gender, body mass index, and the prevalence of hyper-
tension, diabetes mellitus and chronic kidney disease, as well 
as systolic and diastolic blood pressure, fasting plasma glucose 
levels, blood glycosylated hemoglobin (hemoglobin A1c) content 
and serum concentrations of triglycerides and creatinine were 
greater, whereas the serum concentrations of HDL-cholesterol 
and estimated glomerular filtration rate were lower, in the 
subjects with ischemic stroke than in the controls.
We examined the relation of allele frequencies for 
41,339 SNPs that passed quality control to ischemic stroke 
with Fisher's exact test. A Manhattan plot of EWAS for 
ischemic stroke is shown in Fig. 2. After Bonferroni's correc-
tion, 77 SNPs were found to be significantly (P<1.21x10-6) 
associated with ischemic stroke (Table II). The genotype 
distributions of these SNPs were in Hardy-Weinberg equilib-
Table I. Characteristics of the 10,785 subjects in the exome-wide association study for ischemic stroke.
Characteristic Ischemic stroke Controls P-value
No. of subjects 1,575 9,210
Age (years) 71.8±12.2 58.8±13.8 <0.0001
Sex (male/female, %) 58.9/41.1 50.4/49.6 <0.0001
Body mass index (kg/m2) 23.5±3.5 23.1±3.5 <0.0001
Current or former smoker (%) 33.9 37.2 0.0450
Hypertension (%) 79.2 42.4 <0.0001
Systolic blood pressure (mmHg) 147±27 125±20 <0.0001
Diastolic blood pressure (mmHg) 82±16 75±12 <0.0001
Diabetes mellitus (%) 44.0 14.5 <0.0001
Fasting plasma glucose (mmol/l) 7.09±2.88 5.80±1.95 <0.0001
Blood hemoglobin A1c (%) 6.34±1.42 5.70±0.93 <0.0001
Dyslipidemia (%) 58.7 57.6 0.5082
Serum triglycerides (mmol/l) 1.47±0.96 1.38±0.96 <0.0001
Serum HDL-cholesterol (mmol/l) 1.28±0.42 1.62±0.44 <0.0001
Serum LDL-cholesterol (mmol/l) 3.10±0.98 3.13±0.80 0.0208
Chronic kidney disease (%) 36.8 18.8 <0.0001
Serum creatinine (µmol/l) 90.3±115.5 72.9±6804 <0.0001
eGFR (ml m-1 1.73 m-2) 67.7±22.7 74.0±18.1 <0.0001
Hyperuricemia (%) 16.9 16.1 0.4794
Serum uric acid (µmol/l) 329±96 323±90 0.1073
Quantitative data are the means ± SD and were compared between subjects with ischemic stroke and controls with the Mann-Whitney U test. 
Categorical data were compared between the 2 groups with Fisher's exact test. Based on Bonferroni's correction, a P-value of <0.0026 (0.05/19) 
was considered statistically significant. HDL, high density lipoprotein; LDL, low density lipoprotein.
Figure 1. Quantile-quantile plots for P-values of allele frequencies in the EWASs for (A) ischemic stroke, (B) ICH, or (C) SAH. The observed P-values (y-axis) 
are compared with the expected P-values (x-axis) under the null hypothesis, with the values being presented as -log10(P).
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Table II. The 77 SNPs significantly (P<1.21x10-6) associated with ischemic stroke in the exome-wide association study.
  Nucleotide
  (amino acid) Chromosome: MAF P-value Allele
Gene dbSNP substitutiona position (%) (allele) OR 95% CI
TTLL5 rs2833270 C/T 21: 3115036 4.1 5.45x10-112 1.05 0.87-1.27
 rs605066 C/T   6: 139508529 25.6 1.93x10-89 1.02 0.94-1.11
 rs146036604 A/C (L879F) 14: 75783181 1.4 1.09x10-73 0.90 0.65-1.25
 rs12615742 T/C   2: 37768584 47.3 3.80x10-62 1.04 0.96-1.12
TCEB3B rs2010834 A/C (F254C) 18: 47034504 24.5 2.40x10-61 1.02 0.94-1.11
TCF19 rs3130933 G/A   6: 31164308 5.2 1.05x10-53 1.18 1.00-1.39
GABRB3 rs3212335 G/A 15: 26766994 38.9 8.21x10-53 1.02 0.94-1.11
NRXN3 rs6574433 G/A 14: 78319816 26.5 6.14x10-49 0.98 0.90-1.06
UBASH3A rs11203203 G/A 21: 42416077 3.9 7.70x10-44 1.13 0.93-1.37
TBC1D32 rs79221470 T/A (C505S)   6: 121281639 17.8 5.10x10-37 1.01 0.92-1.11
DBT rs140308307 T/C (N13D)   1: 100249784 0.3 2.69x10-36 1.59 0.86-2.94
IL20RA rs191996643 T/C (I43V)   6: 137017065 0.8 2.63x10-31 0.74 0.47-1.18
MMP28 rs117651561 G/A 17: 35766644 13.6 1.80x10-29 1.01 0.90-1.12
C15orf57 rs3803354 T/C 15: 40564790 8.9 3.88x10-27 1.11 0.98-1.27
TMPRSS7 rs147783135 C/T (R692*)   3: 112081004 0.8 3.41x10-26 0.54 0.31-0.94
 rs7752978 A/G   6: 114869897 47.4 1.29x10-24 1.00 0.92-1.08
HMGCS2 rs181428774 G/T (L59M)   1: 119764556 0.3 1.56x10-24 0.49 0.21-1.14
DPF3 rs757572 T/C 14: 72665321 41.2 1.28x10-21 1.07 0.99-1.15
SLC6A4 rs56316081 T/C (I108V) 17: 30221637 0.1 2.54x10-21  ND  ND
OSGEPL1 rs75321854 C/T (A98T)   2: 189755490 4.8 2.31x10-20 1.10 0.93-1.31
S100A3 rs36022742 C/T (R3K)   1: 153548478 1.6 4.16x10-20 0.77 0.55-1.09
ALMS1 rs3820700 G/A (S2576N)   2: 73489683 26.1 6.70x10-20 0.98 0.90-1.08
OR2D2 rs1965209 A/G (S148P) 11: 6892059 12.2 9.24x10-20 1.11 0.99-1.24
 rs9494145 T/C   6: 135111414 31.8 9.77x10-20 0.96 0.88-1.04
AXDND1 rs41267592 C/T (T627M)   1: 179468524 0.3 1.92x10-19 0.61 0.28-1.33
SCMH1 rs182666831 A/T (S48C)   1: 41151649 0.1 5.23x10-19 0.58 0.18-1.92
ELMO1 rs11984075 A/G   7: 37397251 1.1 3.61x10-18 0.78 0.53-1.16
OTOL1 rs12633334 G/A   3: 161452823 45.1 2.34x10-17 0.97 0.89-1.04
 rs5026743 T/G   6: 32472187 29.7 4.27x10-17 1.12 1.03-1.22
MUC16 rs12459532 G/A (P9422L) 19: 8948505 1.8 4.29x10-17 1.42 1.10-1.85
TMPRSS6 rs2235321 G/A 22: 37066886 43.7 7.08x10-17 1.09 1.01-1.18
 rs11624336 G/A 14: 96727175 14.9 2.40x10-16 0.99 0.88-1.10
KIAA1324 rs1052878 C/T (P922L)   1: 109202996 4.9 6.66x10-16 1.05 0.89-1.24
MMP28 rs79742527 G/A 17: 35766662 13.6 1.04x10-15 1.00 0.89-1.11
SERINC1 rs11964202 G/A   6: 122444993 0.6 1.64x10-15 0.87 0.51-1.47
KANK4 rs2258470 C/T (R822H)   1: 62263166 19.3 8.84x10-15 1.13 1.03-1.24
PRR22 rs201451364 C/T (R78H) 19: 5784014 0.1 1.42x10-14 1.54 0.57-4.13
PLCB1 rs6140742 C/G 20: 8838465 36.3 3.52x10-14 1.01 0.94-1.09
AHNAK2 rs150385420 A/G (S4485P) 14: 104941998 2.6 6.43x10-14 0.98 0.77-1.23
FBXO16 rs3735726 C/T (R63Q)   8: 28463730 3.3 4.02x10-13 1.14 0.93-1.39
CALR3 rs3810198 T/C 19: 16490383 28.6 1.45x10-12 1.03 0.95-1.12
PDGFD rs10895547 C/T 11: 103937424 41.0 1.74x10-12 0.99 0.92-1.07
LOC101928877 rs6844558 T/C   4: 185060282 38.5 4.86x10-11 1.02 0.94-1.10
MBD2 rs1145315 T/C 18: 54162585 33.3 1.47x10-10 0.95 0.88-1.03
LRTM1 rs182902370 C/T   3: 54918891 0.9 3.41x10-10 1.10 0.74-1.62
SEC16B rs202187751 G/C (D41H)   1: 177967861 0.2 4.18x10-10 0.53 0.16-1.72
NEURL4 rs117553236 T/G (M1048L) 17: 7321417 0.3 5.35x10-10 0.97 0.41-2.33
PPFIA1 rs546502 G/A (V71I) 11: 70272383 15.9 6.09x10-10 1.18 1.08-1.30
SLC18A1 rs1390938 G/A (T136I)   8: 20179202 25.5 6.98x10-10 1.06 0.97-1.15
DDOST rs74526704 C/T (R396Q)   1: 20652655 0.2 9.25x10-10 0.86 0.34-2.20
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rium (P>0.001) among both subjects with ischemic stroke and 
the controls (data not shown).
Multivariable logistic regression analysis of the relation of 
SNPs to ischemic stroke. The relation of the 77 SNPs iden-
Table II. Continued.
  Nucleotide
  (amino acid) Chromosome: MAF P-value Allele
Gene dbSNP substitutiona position (%) (allele) OR 95% CI
ZNF16 rs139521477 C/T (R669Q)   8: 144930781 0.1 9.85x10-10 0.73 0.22-2.43
TTC16 rs142193455 G/A (R450Q)   9: 127726328 1.1 1.05x10-9 0.60 0.38-0.93
SEMA4D rs13295305 C/T (R713K)   9: 89363482 12.7 1.24x10-9 1.07 0.96-1.20
TRH rs13306057 G/A (G3S)   3: 129975823 0.2 1.47x10-9 0.44 0.14-1.41
MAST4 rs56337909 G/A (S1863N)   5: 67164767 2.7 3.19x10-9 1.01 0.79-1.28
PTPRR rs10784867 C/T 12: 70740947 48.3 4.83x10-9 0.98 0.91-1.06
PREX1 rs6095241 G/A 20: 48692260 41.5 4.95x10-9 1.09 1.01-1.18
 rs12402711 G/A   1: 41413409 27.1 6.95x10-9 1.00 0.92-1.09
 rs10277516 C/A   7: 22869155 3.3 2.30x10-8 1.08 0.88-1.33
ROR2 rs200805854 C/A (E703D)   9: 91724385 0.2 3.93x10-8 0.89 0.35-2.27
DUS4L rs4730250 A/G   7: 107567250 9.4 4.04x10-8 0.91 0.80-1.04
 rs11185362 A/G   1: 104018866 24.2 4.37x10-8 1.04 0.96-1.14
IL7R rs3194051 A/G (I356V)   5: 35876172 7.4 6.06x10-8 1.01 0.87-1.16
FAM200A rs75129401 T/C (H35R)   7: 99548304 1.5 6.08x10-8 0.64 0.44-0.93
PLXNC1 rs75674989 G/T (R614S) 12: 94226656 3.8 6.12x10-8 0.84 0.68-1.03
 rs7131744 G/A 12: 4387114 44.7 7.92x10-8 1.09 1.01-1.18
PDIA5 rs2292661 C/T (T391M)   3: 123150263 0.7 1.03x10-7 0.47 0.26-0.88
GOLGB1 rs3732407 G/C (S911T)   3: 121697776 3.5 1.11x10-7 1.15 0.94-1.41
ARPC1B rs1045012 G/C (K37N)   7: 99386731 1.7 1.97x10-7 0.94 0.70-1.27
ALMS1 rs138921247 G/C (V807L)   2: 73448943 1.8 2.71x10-7 0.87 0.65-1.16
TRIM67 rs1998027 A/G   1: 231190340 33.7 2.80x10-7 0.98 0.90-1.06
C16orf95 rs3748393 A/C (S26A) 16: 87317167 41.7 3.24x10-7 1.06 0.98-1.14
CES5A rs145397395 C/T (V220M) 16: 55866010 0.9 4.76x10-7 0.85 0.76-1.79
ACTR5 rs3752289 C/T (P580L) 20: 38771731 1.4 5.15x10-7 0.98 0.71-1.36
 rs3095354 A/G   6: 30868334 26.7 5.75x10-7 1.12 1.03-1.22
CYP4F12 rs191885206 T/C (C402R) 19: 15696024 0.3 6.57x10-7 2.11 1.23-3.57
CELSR2 rs117684956 G/A (V598M)   1: 109251871 1.3 9.21x10-7 1.25 0.93-1.69
Allele frequencies were analyzed with Fisher's exact test. aMajor allele/minor allele. SNP, single nucleotide polymorphisms; MAF, minor allele 
frequency; OR, odds ratio; CI, confidence interval; ND, not determined.
Figure 2. Manhattan plot for P-values of allele frequencies in the EWAS of ischemic stroke. The P-values (y-axis) are plotted as -log10(P) with respect to the 
physical chromosomal positions of the corresponding SNPs (x-axis). The 4 SNPs (GABRB3, TMPRSS7, PDIA5 and CYP4F12) ultimately found to be related 
to ischemic stroke are indicated.
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tified by EWAS to ischemic stroke was examined further 
by multivariable logistic regression analysis with adjust-
ment for age, sex and the prevalence of hypertension and 
diabetes mellitus (Table III). Four SNPs, rs3212335 (G/A) of 
γ-aminobutyric acid type A receptor β3 subunit (GABRB3), 
rs147783135 [C/T (R692*)] of transmembrane protease, 
serine 7 gene (TMPRSS7), rs2292661 [C/T (T391M)] of 
protein disulfide isomerase family A member 5 gene (PDIA5), 
and rs191885206 [T/C (C402R)] of cytochrome P450 family 4 
subfamily F member 12 gene (CYP4F12) were related (P<0.01 
in at least one genetic model) to ischemic stroke, although 
no SNP was significantly [P<1.62x10-4 (0.05/308)] associated 
with this condition. The minor A and C alleles of rs3212335 
and rs191885206, respectively, were risk factors for ischemic 
stroke, whereas the minor T alleles of rs147783135 and 
rs2292661 were protective against this condition.
EWAS for ICH. The characteristics of the subjects for EWAS 
for ICH are shown in Table IV. Age, the frequency of the 
male gender, and the prevalence of hypertension and diabetes 
mellitus were greater in the subjects with ICH than in the 
controls.
We examined the relation of allele frequencies for 
41,332 SNPs to ICH with Fisher's exact test. A Manhattan plot 
for EWAS for ICH is shown in Fig. 3A. After Bonferroni's 
correction, 48 SNPs were significantly (P<1.21x10-6) associ-
ated with ICH (Table V). The genotype distributions of these 
SNPs were in Hardy-Weinberg equilibrium (P>0.001) both 
among subjects with ICH and among controls (data not shown).
Multivariable logistic regression analysis of the relation of 
SNPs to ICH. The relation of the 48 SNPs identified by EWAS 
to ICH was examined further by multivariable logistic regres-
sion analysis with adjustment for age, sex and the prevalence 
of hypertension. A total of 6 SNPs were related (P<0.05 in 
at least one genetic model) to ICH (Table VI). Among these 
SNPs, rs138533962 [G/A (R379C)] of serine/threonine/tyrosine 
kinase 1 gene (STYK1) (dominant and additive 1 models) was 
significantly [P<2.60x10-4 (0.05/192)] associated with ICH, with 
the minor A allele representing a risk factor for this condition.
EWAS for SAH. The characteristics of the subjects in the 
EWAS for SAH are shown in Table IV. The prevalence of 
hypertension was greater, whereas that of dyslipidemia was 
lower, in the subjects with SAH than in the controls.
We examined the relation of allele frequencies for 
41,332 SNPs to SAH with Fisher's exact test. A Manhattan plot 
for EWAS for SAH is shown in Fig. 3B. After Bonferroni's 
correction, 12 SNPs were significantly (P<1.21x10-6) associ-
ated with SAH (Table VII). The genotype distributions of 
these SNPs were in Hardy-Weinberg equilibrium (P>0.001) 
both among subjects with SAH and among controls (data not 
shown).
Multivariable logistic regression analysis of the relation 
of SNPs to SAH. The relation of the 12 SNPs identified by 
EWAS to SAH was examined further by multivariable logistic 
regression analysis with adjustment for age, sex and the 
prevalence of hypertension. Three SNPs were related (P<0.05) 
to SAH (Table VIII). Among these SNPs, rs117564807 
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[C/T (D919N)] of collagen type XVII α1 chain gene (COL17A1) 
(dominant and additive 1 models) was significantly [P<0.0010 
(0.05/48)] associated with SAH, with the minor T allele being 
protective against this condition.
Relation of SNPs to intermediate phenotypes. We examined 
the relation of 6 SNPs (rs3212335 of GABRB3, rs147783135 
of TMPRSS7, rs2292661 of PDIA5, rs191885206 of 
CYP4F12, rs138533962 of STYK1 and rs117564807 of 
COL17A1) to intermediate phenotypes of ischemic or hemor-
rhagic stroke, including hypertension, diabetes mellitus, 
hypertriglyceridemia, hypo-HDL-cholesterolemia, hyper-
LDL-cholesterolemia, chronic kidney disease, obesity, and 
hyperuricemia. The rs138533962 SNP of STYK1 was signifi-
cantly [P<0.0010 (0.05/48)] associated with the prevalence 
of hypertension, diabetes mellitus, hypertriglyceridemia and 
hypo-HDL-cholesterolemia, whereas the other 5 SNPs were 
not related to any of these intermediate phenotypes (Table IX).
Relation of genes and SNPs identified in the present study to 
phenotypes previously examined in GWASs. We examined the 
6 genes and SNPs identified in the present study to phenotypes 
previously examined by GWASs available in public databases 
[GWAS Catalog (http://www.ebi.ac.uk/gwas) and GWAS 
Table IV. Characteristics of the subjects in the exome-wide association studies for ICH or subarachnoid hemorrhage.
Characteristic Controls ICH P-value SAH P-value
No. of subjects 9158 673  265
Age (years) 58.8±13.9 69.4±13.9 <0.0001 59.4±13.2 0.8515
Sex (male/female, %) 50.4/49.6 62.6/37.4 <0.0001 41.1/58.9 0.0033
Body mass index (kg/m2) 23.1±3.5 23.1±3.8 0.9986 23.1±3.3 0.9672
Current or former smoker (%) 37.1 33.3 0.1836 31.5 0.1590
Hypertension (%) 42.4 81.4 <0.0001 60.5 <0.0001
Diabetes mellitus (%) 14.5 38.1 <0.0001 19.6 0.0345
Dyslipidemia (%) 57.5 51.5 0.0152 41.2 <0.0001
Chronic kidney disease (%) 18.8 21.2 0.2656 28.0 0.0052
Hyperuricemia (%) 16.0 15.6 0.8915 9.4 0.0060
Quantitative data are the means ± SD and were compared between subjects with ICH or SAH and controls with the Mann-Whitney U test. 
Categorical data were compared between 2 groups with Fisher's exact test. Based on Bonferroni's correction, a P-value of <0.0028 (0.05/18) 
was considered statistically significant. ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.
Figure 3. Manhattan plots for P-values of allele frequencies in the EWASs of (A) ICH or (B) SAH. The P-values (y-axis) are plotted as -log10(P) with respect 
to the physical chromosomal positions of the corresponding SNPs (x-axis). The two SNPs ultimately found to be significantly associated with ICH (STYK1) 
or SAH (COL17A1) are indicated.
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Table V. The 48 SNPs significantly (P<1.21x10-6) associated with intracerebral hemorrhage in the exome-wide association study.
  Nucleotide
  (amino acid) Chromosome: MAF P-value Allele
Gene dbSNP substitutiona position (%) (allele) OR 95% CI
RECQL rs146924988 A/G (M1T) 12: 21499569 0.3 8.57x10-103 0.93 0.29-3.00
ATF7IP2 rs13335336 A/G 16: 10465406 17.0 3.91x10-93 1.15 1.00-1.33
SHCBP1 rs11545690 A/C (M60R) 16: 46618297 5.3 3.58x10-76 0.87 0.67-1.13
 rs1405262 T/C   2: 5994808 41.3 6.36x10-70 0.98 0.88-1.10
CAT rs7943316 A/T 11: 34438925 33.7 1.49x10-53 1.02 0.91-1.15
EXOC6B rs1517182 C/A   2: 72508184 1.7 8.40x10-52 0.91 0.59-1.41
RNASE10 rs202109789 G/A (G87S) 14: 20510730 0.2 3.52x10-49 1.00 0.31-3.25
GKN2 rs146849599 C/T (V130M)   2: 68946388 2.7 6.04x10-49 0.82 0.57-1.18
IGSF10 rs78090556 G/A (T981M)   3: 151447039 0.2 1.49x10-48 2.57 1.08-6.25
GFM2 rs77099085 G/T (H92N)   5: 74759397 6.4 5.68x10-46 0.93 0.74-1.17
ADRB2 rs1042713 G/A (G16R)   5: 148826877 49.1 4.57x10-36 1.02 0.92-1.15
SPN rs3764276 C/T 16: 29661882 37.3 5.46x10-36 1.13 1.01-1.26
 rs3135365 T/G   6: 32421478 18.9 4.03x10-32 0.99 0.85-1.14
NAA25 rs12231744 C/T (R876K) 12: 112039251 35.1 1.00x10-30 1.14 1.02-1.28
DNAH11 rs78763603 G/A   7: 21698150 15.3 3.69x10-24 0.99 0.85-1.15
C15orf57 rs3803354 T/C 15: 40564790 8.9 6.29x10-24 0.92 0.76-1.12
BDP1 rs34529158 C/A (P1669Q)   5: 71522303 0.5 3.02x10-23 0.94 0.44-2.04
FLG rs2184953 G/A (H2194Y)   1: 152308306 36.2 9.10x10-21 0.98 0.88-1.10
 rs563694 T/G   2: 168917561 2.1 1.75x10-20 1.24 0.85-1.79
LOC100996813 rs2453589 G/A 17: 19585538 26.0 8.53x10-19 1.09 0.96-1.23
DPF3 rs757572 T/C 14: 72665321 41.2 2.14x10-17 1.03 0.93-1.16
CCDC18 rs3820059 G/A (S172F)   1: 169421916 7.1 2.24x10-15 0.98 0.79-1.22
 rs11624336 G/A 14: 96727175 14.9 1.56x10-14 0.99 0.84-1.15
AXDND1 rs41267592 C/T (T627M)   1: 179468524 0.3 1.65x10-14 0.62 0.19-1.97
 rs13234712 G/A   7: 119939419 38.8 1.39x10-13 0.98 0.88-1.10
MAPT rs3785879 C/A 17: 45908270 40.8 8.89x10-12 0.95 0.85-1.06
NLRP13 rs17711239 T/C (N781S) 19: 55907897 9.3 1.57x10-11 1.05 0.87-1.27
AIF1 rs2857697 A/G   6: 31617442 34.1 1.84x10-11 1.19 1.06-1.34
STYK1 rs138533962 G/A (R379C) 12: 10620278 2.0 3.90x10-11 401.7 100.0-995.0
CCDC169 rs9546897 T/C (K120R) 13: 36254100 34.6 3.74x10-10 1.04 0.93-1.16
HMHA1 rs150294461 G/A (G654E) 19: 1080682 1.4 4.63x10-10 1.12 0.69-1.79
TJP3 rs1046268 C/T (T898M) 19: 3750617 29.5 5.56x10-10 1.00 0.88-1.13
PAX5 rs2297105 A/C   9: 37020625 48.3 7.69x10-10 0.98 0.88-1.09
 rs4996815 G/T 13: 105999312 12.6 8.66x10-10 1.03 0.88-1.22
HLA-DPB1 rs9277471 A/G   6: 33085905 43.6 1.55x10-9 1.01 0.90-1.12
SSC4D rs10227141 C/T (R505G)   7: 76390273 14.4 4.91x10-9 0.94 0.80-1.10
ZCCHC11 rs138145860 A/G (I1270T)   1: 52445800 0.2 1.04x10-8 0.93 0.29-2.99
MOGAT1 rs35959734 G/A (A13T)   2: 222671822 1.2 1.11x10-8 0.82 0.49-1.39
 rs6534076 C/T   4: 118030971 38.4 1.38x10-8 0.96 0.85-1.07
SPATC1L rs113710653 C/T (E231K) 21: 46161921 1.9 3.75x10-8 3.64 2.43-5.44
LRRC17 rs3800939 A/G (K119E)   7: 102934268 14.0 3.90x10-8 0.97 0.82-1.13
PATE1 rs2114084 A/G (Q47R) 11: 125747715 36.4 2.19x10-7 1.10 0.98-1.23
LY6G6C rs117894946 G/C (G75A)   6: 31719250 9.5 2.77x10-7 1.06 0.88-1.28
VWA5B1 rs139281890 G/A (R92Q)   1: 20312971 0.2 3.26x10-7 0.44 0.06-3.23
PABPC4 rs4660293 A/G   1: 39562508 15.2 3.99x10-7 1.10 0.95-1.28
ELMO1 rs11984075 A/G   7: 37397251 1.1 5.49x10-7 1.04 0.62-1.74
C2 rs511294 A/C   6: 31921092 0.6 7.29x10-7 1.20 0.63-2.30
 rs2823962 G/A 21: 16673913 32.8 8.40x10-7 0.99 0.88-1.11
Allele frequencies were analyzed with Fisher's exact test. aMajor allele/minor allele. SNPs, single nucleotide polymorphisms; MAF, minor 
allele frequency; OR, odds ratio; CI, confidence interval.
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Central (http://www.gwascentral.org/browser)]. None of these 
genes or SNPs was found to be associated with ischemic or 
hemorrhagic stroke in previous GWASs (data not shown).
Discussion
The pathogenesis of ischemic stroke is predominantly 
attributed to atherothrombosis of the cerebral arteries, with 
its treatable risk factors including hypertension, diabetes 
mellitus and chronic kidney disease (1). In addition to these 
conventional risk factors, genetic variants are important in the 
development of ischemic stroke (2). ICH is typically a mani-
festation of underlying small-vessel disease. Long-standing 
hypertension can thus lead to hypertensive vasculopathy and 
consequent microscopic degenerative changes in the walls of 
small to medium penetrating vessels (13). Cerebral amyloid 
angiopathy is characterized by the deposition of the β-amyloid 
peptide in the walls of small leptomeningeal and cortical 
vessels, which can also ultimately result in degenerative 
changes in the vessel wall including loss of smooth muscle 
cells, wall thickening, luminal narrowing, microaneurysm 
formation and microhemorrhages (14-17). Spontaneous SAH 
usually results from a ruptured intracranial aneurysm. Blood 
in the subarachnoid space gives rise to chemical meningitis 
that commonly increases intracranial pressure for days or a 
few weeks. Secondary vasospasm may then cause focal brain 
ischemia. Brain edema accelerates vasospasm and subse-
quent infarction (21,22). Given the serious nature of both 
ischemic and hemorrhagic stroke, prediction of the risk for 
these conditions on the basis of genetic variants would be of 
benefit for decision-making with regard to how aggressively 
to target the clinical risk factors that are currently amenable 
to treatment.
In this study, we demonstrated that rs3212335 (G/A) of 
GABRB3, rs147783135 [C/T (R692*)] of TMPRSS7, rs2292661 
[C/T (T391M)] of PDIA5 and rs191885206 [T/C (C402R)] of 
CYP4F12 were related to ischemic stroke in Japanese indi-
viduals. The minor A allele of rs3212335 and the C allele of 
rs191885206 were risk factors for ischemic stroke, whereas the 
minor T alleles of rs147783135 and rs2292661 were protec-
tive against this condition. We also found that rs138533962 
[G/A (R379C)] of STYK1 was significantly associated with 
ICH, with the minor A allele representing a risk factor for 
ICH, and that rs117564807 [C/T (D919N)] of COL17A1 was 
significantly associated with SAH, with the minor T allele 
being protective against this condition.
SNPs associated with ischemic stroke. The GABRB3 gene 
is located at chromosomal region 15q12 (NCBI Gene, 
https://www.ncbi.nlm.nih.gov/gene) and is highly expressed in 
the brain (The Human Protein Atlas, http://www.proteinatlas.
org). The GABRB3 protein is a component of a multisub-
unit Cl- channel that serves as a receptor for γ-aminobutyric 
acid (GABA), a major inhibitory neurotransmitter of the 
mammalian nervous system (41). Mutations of GABRB3 have 
been associated with several disorders, including Angelman 
syndrome (42), Prader-Willi syndrome (43), non-syndromic 
orofacial clefts (44), epilepsy (45) and autism (46). In this study, 
we demonstrated that rs3212335 (G/A) of GABRB3 was related 
to ischemic stroke, with the minor A allele being a risk factor 
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for this condition, although the molecular mechanism under-
lying this association remains unclear.
TMPRSS7 is located at chromosomal region 3q13.2 
(NCBI Gene) and is highly expressed in the testis (The Human 
Protein Atlas). The TMPRSS7 protein belongs to the type II 
transmembrane serine protease (TTSP) family, the 17 human 
members of which degrade components of the extracellular 
matrix (47) and play physiological and pathological roles in 
digestion, cardiac function, blood pressure regulation, hearing, 
iron metabolism, and epithelial homeostasis (48,49). They have 
also been implicated in tumor growth, invasion and metas-
tasis (48,49), and the genetic variants of TMPRSS7 have been 
associated with the risk for and prognosis of breast cancer (50). 
In this study, we demonstrated that rs147783135 [C/T (R692*)] 
of TMPRSS7 was related to ischemic stroke, with the minor 
T allele being protective against this condition. Given the 
potential roles of TMPRSS7 in tumor growth and blood pressure 
regulation (48,49) the association of this gene with ischemic 
stroke may reflect an effect on atherosclerosis or blood pressure.
PDIA5 is located at chromosomal region 3q21.1 
(NCBI Gene) and is expressed widely including in the brain 
and vascular smooth muscle (The Human Protein Atlas). 
PDIA5 encodes one of the protein disulfide isomerases that 
catalyze protein folding and thiol-disulfide interchange 
reactions in the endoplasmic reticulum (ER). The PDIA5 
protein contains an NH2-terminal ER signal sequence, three 
catalytically active thioredoxin domains, a thioredoxin-like 
domain, and a COOH-terminal ER retention sequence. The 
thioredoxin-like domain is the primary binding site for the 
major ER chaperone calreticulin (51,52). Recent GWASs 
indicated that a SNP in PDIA5 was associated with plasma 
fibrinogen concentration (53) and platelet count (54). In this 
study, we demonstrated that rs2292661 [C/T (T391M)] of 
PDIA5 was related to ischemic stroke, with the minor T allele 
being protective against this condition. Given its potential 
role as a determinant of fibrinogen concentration and platelet 
count, both of which are important in the development of 
atherosclerotic thrombosis, the association of PDIA5 with 
ischemic stroke may reflect an effect of this gene on arterial 
thrombosis.
CYP4F12 is located at chromosomal region 19p13.12 
(NCBI Gene) and is expressed in various tissues and organs 
including the brain and vascular smooth muscle (The Human 
Protein Atlas). CYP4F12 encodes a member of the cyto-
chrome P450 superfamily of monooxygenases that catalyze 
many reactions including those related to drug metabolism, as 
well as to the synthesis of cholesterol, steroids and other lipids. 
The CYP4F12 protein is likely localized to the ER (55,56). 
Given that human CYP4F enzymes play a role in the 
metabolism of endogenous compounds such as inflammatory 
mediators, they likely contribute to regulation of inflammatory 
processes (57). Arachidonic acid and prostaglandin H2 (PGH2) 
have been found to serve as substrates of CYP4F12, which also 
metabolizes to a lesser extent PGE2, PGF2α and leukotriene 
B4 (57,58). In this study, we demonstrated that rs191885206 
[T/C (C402R)] of CYP4F12 was related to ischemic stroke, 
with the minor C allele representing a risk factor for this 
condition. The association of CYP4F12 with ischemic stroke 
may reflect an effect of this gene on vascular inflammation.
A SNP associated with ICH. The STYK1 gene is located at 
chromosomal region 12p13.2 (NCBI Gene) and is expressed 
in various tissues and organs, including the brain (The Human 
Protein Atlas). STYK1 plays important roles in diverse cellular 
and developmental processes, including cell proliferation, 
differentiation and survival (59,60). The upregulation of STYK1 
Table VII. The 12 SNPs significantly (P<1.21x10-6) associated with subarachnoid hemorrhage in the exome-wide association 
study.
  Nucleotide
  (amino acid) Chromosome: MAF P-value Allele
Gene dbSNP substitutiona position (%) (allele) OR 95% CI
CDL6 rs2972146 A/C   2: 226235982 8.7 1.28x10-18 0.98 0.72-1.33
 rs3135365 T/G   6: 32421478 18.9 9.71x10-15 0.86 0.68-1.09
 rs2282978 T/C   7: 92635096 10.6 3.91x10-12 1.23 0.95-1.59
 rs2639889 A/G 16: 61089243 32.3 4.23x10-11 0.88 0.72-1.06
ANKFN1 rs12449568 T/C 17: 56352794 42.0 3.64x10-10 0.92 0.77-1.09
CHRDL2 rs79893604 G/A (P395L) 11: 74697229 0.8 5.70x10-10 2.45 1.23-4.76
CTNNA3 rs12256826 C/T 10: 66214832 13.6 8.96x10-10 0.83 0.63-1.09
SLC4A5 rs10177833 A/C   2: 74230591 46.8 7.03x10-9 0.99 0.84-1.18
TEX41 rs2381683 A/G   2: 144981989 2.7 1.15x10-8 1.14 0.67-1.91
PYGM rs589691 T/C 11: 64757744 42.2 1.25x10-8 1.06 0.89-1.27
 rs34429154 A/C   1: 4303675 40.2 1.47x10-8 1.04 0.87-1.24
COL17A1 rs117564807 C/T (D919N) 10: 104040357 1.1 4.83x10-7 0.00 ND
Allele frequencies were analyzed with Fisher's exact test. aMajor allele/minor allele. SNPs, single nucleotide polymorphisms; MAF, minor 
allele frequency; OR, odds ratio; CI, confidence interval; ND, not determined.
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expression has been detected in many types of tumor, including 
breast cancer (61), lung cancer (62), ovarian cancer (63), prostate 
cancer (64), colorectal cancer (65) and hepatocellular carci-
noma (66). The STYK1 protein has been shown to promote 
cell transformation, tumorigenesis and metastasis by activating 
the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway 
and inactivating glycogen synthase kinase 3β signaling (67). It 
has also been found to enhance angiogenesis and to change the 
morphology of blood vessels during tumor growth (68). In this 
study, we demonstrated that rs138533962 [G/A (R379C)] of 
STYK1 was significantly associated with ICH, with the minor 
A allele representing a risk factor for this condition. The rela-
tion of STYK1 to ICH may be attributable to an effect of this 
gene on the remodeling of blood vessels in the brain, although 
the molecular mechanism underlying this association remains 
to be determined.
A SNP associated with SAH. The COL17A1 gene is located 
at chromosomal region 10q25.1 (NCBI Gene) and is highly 
expressed in skin (The Human Protein Atlas). Collagen XVII 
is a homotrimer of three 180-kDa α1 chains, each of which 
possesses a long intracellular NH2-terminal domain, a short 
transmembrane region, and an extracellular COOH-terminus. 
It is a structural component of hemidesmosomes, which 
mediate the adhesion of epidermal keratinocytes and certain 
other types of epithelial cell to the underlying basement 
membrane (69,70). Mutations in COL17A1 that result in the 
generation of premature stop codons are associated with 
non-Herlitz junctional epidermolysis bullosa (69,70), which 
is characterized by generalized blistering of the skin and 
mucous membranes together with atrophic scarring and nail 
dystrophy. The majority of patients with such mutations lack 
type XVII collagen mRNA as a result of nonsense-mediated 
mRNA decay (71). In addition, an autoimmune response to 
collagen XVII is responsible for epidermal impairment in 
individuals with bullous pemphigoid (72). A population-
based study revealed an association of bullous pemphigoid 
with neurological disorders, in particular stroke, for which 
the odds ratio was 3.3 (73). This association is likely due to 
the fact that the inflammatory state present in individuals 
with bullous pemphigoid is not confined to the skin but 
also involves the vascular endothelium (74,75). It has been 
suggested that intracranial aneurysm is a chronic inflamma-
tory disease at bifurcation sites of cerebral arterial walls (76). 
Indeed, many inflammatory cells have been detected in speci-
mens of surgically dissected intracranial vessel walls affected 
by aneurysm (77). Chronic vascular inflammation, acting 
together with the structural properties of the cerebral arte-
rial wall and hemodynamic factors, may therefore accelerate 
the development of intracranial aneurysm and subsequent 
aneurysm rupture. We have now shown that rs117564807 
[C/T (D919N)] of COL17A1 was significantly associated with 
SAH, with the minor T allele being protective against this 
condition. The genotype distribution of rs117564807 was 
265/265 (100%) CC in subjects with SAH and 8958/9158 
(97.82%) CC, 197/9158 (2.15%) CT, and 3/9158 (0.03%) TT 
in control individuals, giving an allele odds ratio of 0. The 
association of COL17A1 with SAH may be attributable to the 
effect of this gene on cerebrovascular inflammation, although 
the molecular mechanism remains to be determined.
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General considerations. In previous meta-analyses of GWASs 
for ischemic stroke, the MAF of most SNPs ranged from 
6 to 49% and the odds ratio from 0.8 to 2.0 (4-12,34-36). 
In our study, we identified four SNPs related to ischemic 
stroke, with the allele odds ratio (MAF, %) of rs3212335 of 
GABRB3, rs147783135 of TMPRSS7, rs2292661 of PDIA5, 
and rs191885206 of CYP4F12 being 1.02 (38.9%), 0.54 (0.8%), 
0.47 (0.7%), and 2.11 (0.3%), respectively. Whereas rs3212335 
of GABRB3 was thus a common variant with a small effect 
size, the other three SNPs were low-frequency or rare variants 
with a moderate effect size.
A meta-analysis of GWASs identified rs11179580 at 
12q21.1 and rs156197380 at 1q22 as susceptibility loci for 
lobar and nonlobar ICH, respectively, in European ancestry 
populations (20). The odds ratio (MAF, %) was 1.56 (24%) 
for rs11179580 and 1.44 (32%) for rs156197380. Previous 
GWASs (26-31) and a meta-analysis of GWASs (32) also identi-
fied SNPs associated with intracranial aneurysm. The MAFs 
of these SNPs ranged from 15 to 48% and the odds ratios from 
0.47 to 2.22. Another recent GWAS of intracranial aneurysm 
identified low-frequency genetic variants with MAFs of 3 to 5% 
and odds ratios of ~2.0 (78). We have now identified two SNPs 
significantly associated with hemorrhagic stroke, with the odds 
ratio (MAF, %) of rs138533962 of STYK1 and rs117564807 of 
COL17A1 being 111.3 (2.0%) and 2.23x10-8 (1.1%), respectively. 
Both of these SNPs were thus low-frequency variants with a 
large effect size.
There are several limitations to the present study: i) The 
inflation factors for ischemic stroke, ICH, and SAH were rela-
tively high, which may be attributable to the relatively small 
numbers of subjects with ischemic and hemorrhagic stroke. 
Given that our results were not replicated, they will require 
validation in other independent subject panels or in other 
ethnic groups; ii) it is possible that rs3212335 of GABRB3, 
rs147783135 of TMPRSS7, rs2292661 of PDIA5, rs191885206 of 
CYP4F12, rs138533962 of STYK1 or rs117564807 of COL17A1 
is in linkage disequilibrium with other polymorphisms in the 
same gene or in other nearby genes that are actually respon-
sible for the development of ischemic or hemorrhagic stroke; 
iii) the functional relevance of these SNPs to the pathogenesis 
of ischemic stroke, ICH, or SAH remains to be elucidated.
In conclusion, our results suggest that rs3212335 (G/A) of 
GABRB3, rs147783135 [C/T (R692*)] of TMPRSS7, rs2292661 
[C/T (T391M)] of PDIA5, and rs191885206 [T/C (C402R)] 
of CYP4F12 may be novel susceptibility loci for ischemic 
stroke, whereas rs138533962 [G/A (R379C)] of STYK1 and 
rs117564807 [C/T (D919N)] of COL17A1 may be such loci 
for ICH and SAH, respectively, in Japanese individuals. 
Determination of genotypes for these SNPs may prove 
informative for assessment of the genetic risk for ischemic or 
hemorrhagic stroke in Japanese individuals.
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